Revive Therapeutics Announces LOI to Acquire DiagnaMed’s Molecular Hydrogen Program

by rvvadmin | Mar 3, 2025 | 2025

TORONTO, March 03, 2025 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and...

Revive Therapeutics Announces Update on R&D Focus on Bucillamine for Infectious Diseases and Medical Countermeasures

by rvvadmin | Feb 3, 2025 | 2025

TORONTO, Feb. 03, 2025 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical...

Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

by rvvadmin | Jan 8, 2025 | 2025

TORONTO, Jan. 08, 2025 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical...

Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke

by rvvadmin | Nov 12, 2024 | 2024

TORONTO, Nov. 12, 2024 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, medical countermeasures...

Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

by rvvadmin | Oct 31, 2024 | 2024

TORONTO, Oct. 31, 2024- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures,...